Jozefa Wesierska-Gadek

Jozefa Wesierska-Gadek

UNVERIFIED PROFILE

Are you Jozefa Wesierska-Gadek?   Register this Author

Register author
Jozefa Wesierska-Gadek

Jozefa Wesierska-Gadek

Publications by authors named "Jozefa Wesierska-Gadek"

Are you Jozefa Wesierska-Gadek?   Register this Author

80Publications

496Reads

25Profile Views

Targeting p53 as a promising therapeutic option for cancer by re-activating the wt or mutant p53's tumor suppression.

Future Med Chem 2018 04 23;10(7):755-777. Epub 2018 Mar 23.

Cell Cycle Regulation Group, Department of Medicine, Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4155/fmc-2017-0175DOI Listing
April 2018

Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.

Future Med Chem 2016 Jan 21;8(1):55-72. Epub 2015 Dec 21.

Cell Cycle Regulation Group, Department of Medicine, Div: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.future-science.com/doi/10.4155/fmc.15.155
Publisher Site
http://dx.doi.org/10.4155/fmc.15.155DOI Listing
January 2016

Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.

J Cell Biochem 2015 Dec;116(12):2824-39

Department of Medicine I, Institute of Cancer Research, Comprehensive Cancer Center, Cell Cycle Regulation Group, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.25229DOI Listing
December 2015

Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.

J Cancer Prev 2014 Jun;19(2):125-36

Cell Cycle Regulation Group, Department of Medicine I, Division: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15430/JCP.2014.19.2.125DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204161PMC
June 2014

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.

Biochem Pharmacol 2012 Nov 14;84(10):1318-31. Epub 2012 Aug 14.

Cell Cycle Regulation Group, Dept. of Medicine I, Div.: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2012.07.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494830PMC
November 2012

The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.

Future Med Chem 2012 Mar;4(4):395-424

Cell Cycle Regulation Group, Division: Institute of Cancer Research, Dept of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.future-science.com/doi/10.4155/fmc.12.12
Publisher Site
http://dx.doi.org/10.4155/fmc.12.12DOI Listing
March 2012

Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.

Future Med Chem 2012 Jan;4(1):51-72

Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4155/fmc.11.175DOI Listing
January 2012

The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.

Expert Opin Investig Drugs 2011 Dec 21;20(12):1611-28. Epub 2011 Oct 21.

Medical University of Vienna, Department of Medicine I, Institute of Cancer Research, Comprehensive Cancer Center, Cell Cycle Regulation Group, Borschkegasse 8a, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.2011.628985DOI Listing
December 2011

Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms.

Curr Pharm Des 2011 ;17(3):256-71

Cell Cycle Regulation Group, Department of Medicine Div.: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/138161211795049714DOI Listing
September 2011

Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.

J Cell Biochem 2011 Apr;112(4):1103-17

Cell Cycle Regulation Group, Institute of Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.23024DOI Listing
April 2011

Triazoloacridone C-1305 abrogates the restriction checkpoint in cells lacking functional p53 and promotes their accumulation in the G2/M phase of the cell cycle.

J Exp Ther Oncol 2011 ;9(1):5-15

Cell Cycle Regulation Group, Institute of Cancer Research, Dept. of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
March 2011

Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.

J Exp Ther Oncol 2011 ;9(1):17-25

Cell Cycle Regulation Group, Division, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
March 2011

Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells.

J Exp Ther Oncol 2011 ;9(1):27-35

Cell Cycle Regulation Group, Division, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
March 2011

Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.

J Exp Ther Oncol 2011 ;9(1):37-45

Cell Cycle Regulation Group, Div., Institute of Cancer Research, Dept. of Medicine I, Medical University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
March 2011

Combining an FPTase inhibitor with cisplatin facilitates induction of apoptosis in human A549 lung cancer cells.

J Exp Ther Oncol 2011 ;9(1):53-65

Cell Cycle Regulation Group, Div.: Institute of Cancer Research, Dept. of Medicine I, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
March 2011

Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.

J Cell Biochem 2011 Mar;112(3):761-72

Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.23004DOI Listing
March 2011

Whether to target single or multiple CDKs for therapy? That is the question.

J Cell Physiol 2011 Feb;226(2):341-9

Cell Cycle Regulation Group, Div., Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.22426DOI Listing
February 2011

Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.

J Cell Biochem 2011 Jan;112(1):273-88

Dept. of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.22918DOI Listing
January 2011

mTOR and its link to the picture of Dorian Gray - re-activation of mTOR promotes aging.

Aging (Albany NY) 2010 Dec;2(12):892-3

Cell Cycle Regulation Group, Div., Institute of Cancer Research, Department of Medicine, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034175PMC
http://dx.doi.org/10.18632/aging.100240DOI Listing
December 2010

[Biological activity of poly(ADP-ribose)polymerase-1].

Postepy Hig Med Dosw (Online) 2010 Jul 30;64:344-63. Epub 2010 Jul 30.

Zakład Biochemii Medycznej, Katedra Cytobiochemii Uniwersytetu Łódzkiego, 90-237 Łódź.

View Article

Download full-text PDF

Source
July 2010

Tubulohelical membrane arrays: From the initial observation to the elucidation of nanophysical properties and cellular function.

PMC Biophys 2010 Jun 28;3(1):13. Epub 2010 Jun 28.

Department of Biochemistry and Cell Biology, Max F, Perutz Laboratories, University of Vienna, Dr, Bohrgasse 9, A-1030 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1757-5036-3-13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917399PMC
June 2010

Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.

Biochem Pharmacol 2010 May 11;79(10):1387-97. Epub 2010 Jan 11.

Department of Pharmaceutical Technology and Biochemistry, Gdansk University of Technology, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2009.12.023DOI Listing
May 2010

Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.

Acta Biochim Pol 2009 31;56(3):495-501. Epub 2009 Aug 31.

Cell Cycle Regulation Group, Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, Vienna, Austria.

View Article

Download full-text PDF

Source
January 2010

Novel potent pharmacological cyclin-dependent kinase inhibitors.

Future Med Chem 2009 Dec;1(9):1561-81

Cell Cycle Regulation Group, Department of Medicine, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.future-science.com/doi/10.4155/fmc.09.110
Publisher Site
http://dx.doi.org/10.4155/fmc.09.110DOI Listing
December 2009

Oncogenes do not Fully Override Cell-intrinsic Traits: Pronounced Impact of the Cellular Programme.

Cancer Microenviron 2009 Sep 4;2(Suppl 1):215-25. Epub 2009 Sep 4.

Cell Cycle Regulation Group, Div. Institute of Cancer Research, Dept. of Medicine I, Medical University of Vienna, Borschkegasse 8 a, Vienna, A-1090 Austria ; Christian Doppler Laboratory on Molecular Cancer Chemoprevention, Department of Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, A-1090 Austria.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12307-009-0024-9
Publisher Site
http://dx.doi.org/10.1007/s12307-009-0024-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2756341PMC
September 2009

Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?

Ann N Y Acad Sci 2009 Aug;1171:228-41

Cell Cycle Regulation Group, Department of Medicine I, Division Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1749-6632.2009.04726.xDOI Listing
August 2009

Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?

Ann N Y Acad Sci 2009 Aug;1171:242-9

Cell Cycle Regulation Group, Division Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1749-6632.2009.04700.xDOI Listing
August 2009

Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.

Ann N Y Acad Sci 2009 Aug;1171:250-6

Department of Medicine I, Div Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1749-6632.2009.04717.xDOI Listing
August 2009

Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose.

Ann N Y Acad Sci 2009 Aug;1171:257-63

Department of Medicine I, Institute of Cancer Research, Medical University Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1749-6632.2009.04884.x
Publisher Site
http://dx.doi.org/10.1111/j.1749-6632.2009.04884.xDOI Listing
August 2009

Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.

J Cell Biochem 2009 Jun;107(3):428-37

Laboratory of Growth Regulators, Faculty of Science, Palacký University & Institute of Experimental Botany, 783 71 Olomouc, Czech Republic.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcb.22139
Publisher Site
http://dx.doi.org/10.1002/jcb.22139DOI Listing
June 2009

p53-mediated regulation of cell cycle progression: pronounced impact of cellular microenvironment.

J Cell Physiol 2009 May;219(2):459-69

Cell Cycle Regulation Group, Division: Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.21705DOI Listing
May 2009

Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment.

J Cell Biochem 2009 Apr;106(5):937-55

Cell Cycle Regulation Group, Department of Medicine I, Div. Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.22074DOI Listing
April 2009

Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.

Biochem Pharmacol 2008 Dec 12;76(11):1554-62. Epub 2008 Aug 12.

Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8 a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2008.08.002DOI Listing
December 2008

Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells.

Biochem Pharmacol 2008 Dec 12;76(11):1503-14. Epub 2008 Aug 12.

Cell Cycle Regulation Group, Department of Medicine I, Div.: Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2008.07.040DOI Listing
December 2008

Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells.

J Cell Biochem 2008 Dec;105(5):1161-71

Cell Cycle Regulation Group, Div.: Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.21903DOI Listing
December 2008

[New face of antiapoptotic proteins. I. Protein Mcl-1].

Postepy Biochem 2007 ;53(3):228-38

Katedra Cytobiochemii Uniwersytetu Lódz-kiego, Lódz.

View Article

Download full-text PDF

Source
June 2008

[New face of antiapoptotic proteins. II. Survivin].

Postepy Biochem 2007 ;53(3):239-53

Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
June 2008

Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen.

J Cell Biochem 2008 May;104(1):27-37

Cell Cycle Regulation Group, Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.21595DOI Listing
May 2008

A combined treatment of HeLa cells with the farnesyl protein transferase inhibitor L-744,832 and cisplatin significantly increases the therapeutic effect as compared to cisplatin monotherapy.

J Cell Biochem 2008 May;104(1):189-201

Cell Cycle Regulation Group, Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcb.21612
Publisher Site
http://dx.doi.org/10.1002/jcb.21612DOI Listing
May 2008

Signaling of DNA damage is not sufficient to induce p53 response: (re)activation of wt p53 protein strongly depends on cellular context.

J Cell Biochem 2008 Apr;103(5):1607-20

Cell Cycle Regulation Group, Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8 a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.21548DOI Listing
April 2008

Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.

Food Chem Toxicol 2008 Apr 11;46(4):1327-33. Epub 2007 Sep 11.

Cell Cycle Regulation Group, Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8 a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fct.2007.09.004DOI Listing
April 2008

A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein.

J Cell Biochem 2007 Dec;102(6):1405-19

Cell Cycle Regulation Group, Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcb.21596
Publisher Site
http://dx.doi.org/10.1002/jcb.21596DOI Listing
December 2007

Inhibition of farnesyl protein transferase sensitizes human MCF-7 breast cancer cells to roscovitine-mediated cell cycle arrest.

J Cell Biochem 2007 Oct;102(3):736-47

Department of Medicine I, Div.: Institute of Cancer Research, Vienna Medical University, Vienna, Austria.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcb.21325
Publisher Site
http://dx.doi.org/10.1002/jcb.21325DOI Listing
October 2007

Phenol red in the culture medium strongly affects the susceptibility of human MCF-7 cells to roscovitine.

Cell Mol Biol Lett 2007 19;12(2):280-93. Epub 2007 Jan 19.

Institute of Cancer Research, Department of Medicine I, Vienna Medical University, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/s11658-007-0002-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276014PMC
August 2007

Cellular and organismal ageing: Role of the p53 tumor suppressor protein in the induction of transient and terminal senescence.

J Cell Biochem 2007 Aug;101(6):1355-69

Cell Cycle Regulation Group, Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.21383DOI Listing
August 2007

Characterization of autoantibodies against components of the nuclear pore complexes: high frequency of anti-p62 nucleoporin antibodies.

Ann N Y Acad Sci 2007 Aug;1109:519-30

Cell Cycle Regulation Group, Div.: Institute of Cancer Research, Department of Medicine I, Vienna Medical University, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1398.058DOI Listing
August 2007

Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.

J Cell Biochem 2007 Mar;100(4):865-74

Cell Cycle Regulation Group, Division: Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8 a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.21211DOI Listing
March 2007

Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells.

Ann N Y Acad Sci 2007 Jan;1095:45-52

Cell Cycle Regulation Group, Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8 A, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1397.006DOI Listing
January 2007

Prevention of farnesylation of c-Ha-Ras protein enhances synergistically the cytotoxic action of doxorubicin in cycling but not in quiescent cells.

J Cell Biochem 2006 Dec;99(6):1664-76

Cell Cycle Regulation Group, Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.21028DOI Listing
December 2006

Prevention of p53 degradation in human MCF-7 cells by proteasome inhibitors does not mimic the action of roscovitine.

Ann N Y Acad Sci 2006 Dec;1090:234-44

Division: Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8 a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1196/annals.1378.026DOI Listing
December 2006

Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells.

J Cell Biochem 2006 Aug;98(6):1367-79

Department of Medicine I, Division: Institute of Cancer Research, Cell Cycle Regulation Group, Vienna Medical University, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.20960DOI Listing
August 2006

Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors.

Mol Neurobiol 2006 Aug;34(1):27-50

Department of Medicine I, Institute of Cancer Research and Cell Cycle Regulation Group, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1385/mn:34:1:27DOI Listing
August 2006

Advantage of a baculovirus expression system for protein-protein interaction studies. Involvement of posttranslational phosphorylation in the interaction between wt p53 protein and poly(ADP-ribose) polymerase-1.

Acta Biochim Pol 2005 4;52(3):713-9. Epub 2005 Aug 4.

Cell Cycle Regulation Group, Division: Institute of Cancer Research, Department of Medicine I, Vienna Medical University, Vienna, Austria.

View Article

Download full-text PDF

Source
May 2006

Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis.

Hepatology 2006 May;43(5):1135-44

First Department of Internal Medicine, Institute of Cancer Research, Vienna Medical University, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.21172DOI Listing
May 2006

Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.

Expert Opin Investig Drugs 2006 Jan;15(1):23-38

Division Institute of Cancer Research, Dept. of Medicine I, Cell Cycle Regulation Group, Medical University of Vienna, Borschkegasse 8 a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/13543784.15.1.23DOI Listing
January 2006

The subcellular distribution of the p53 tumour suppressor, and organismal ageing.

Cell Mol Biol Lett 2005 ;10(3):439-53

Cell Cycle Regulation Group, Div. Institute of Cancer Research, Dept. of Medicine I, Vienna Medical University, Borschkegasse 8 a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
December 2005

A new multiplex assay allowing simultaneous detection of the inhibition of cell proliferation and induction of cell death.

J Cell Biochem 2005 Sep;96(1):1-7

Department of Medicine I, Cell Cycle Regulation Group, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.20531DOI Listing
September 2005

Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action.

J Cell Biochem 2005 Aug;95(5):1012-28

Department of Medicine I, Cell Cycle Regulation Group, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.20467DOI Listing
August 2005

Antinuclear antibodies in primary biliary cirrhosis.

Semin Liver Dis 2005 Aug;25(3):298-310

Department of Medicine, Surgery and Dentistry, San Paolo School of Medicine, University of Milan, Italy.

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/s-2005-916321
Publisher Site
http://dx.doi.org/10.1055/s-2005-916321DOI Listing
August 2005

Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells.

Mol Cancer Ther 2005 Jan;4(1):113-24

Cell Cycle Regulation Group, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8 a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
January 2005

Role of PARP on iNOS pathway during endotoxin-induced acute lung injury.

Intensive Care Med 2004 Jul 10;30(7):1421-31. Epub 2004 Jun 10.

Department of Anesthesiology, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00134-004-2301-xDOI Listing
July 2004

Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest.

Cancer Res 2004 Jul;64(13):4487-97

Cell Cycle Regulation Group, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-03-3410DOI Listing
July 2004

Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin.

Pol J Pharmacol 2003 Sep-Oct;55(5):895-902

Cell Cycle Regulation Group, Institute of Cancer Research, University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
June 2004

Platelet-endothelial cell interaction in pulmonary micro-circulation: the role of PARS.

Thromb Haemost 2004 Apr;91(4):761-70

Department of Anesthesiology, Ludwig Maximilians University, Marchioninistr. 15, 81377 Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1160/TH03-11-0685DOI Listing
April 2004

Induction of cell cycle arrest and apoptosis in human cervix carcinoma cells during therapy by cisplatin.

Cancer Detect Prev 2003 ;27(6):481-93

Cell Cycle Regulation Group, Institute of Cancer Research, Faculty of Medicine, University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cdp.2003.07.002DOI Listing
March 2004

Role of poly(ADP-ribose) synthetase in pulmonary leukocyte recruitment.

Am J Physiol Lung Cell Mol Physiol 2003 Nov 18;285(5):L996-L1005. Epub 2003 Jul 18.

Department of Anesthesiology, University of Munich, 81377 Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajplung.00144.2003DOI Listing
November 2003

Strong induction of p73 protein in vivo coincides with the onset of apoptosis in rat liver after treatment with the hepatocarcinogen N-nitrosomorpholine (NNM).

J Cell Biochem 2003 Nov;90(4):837-55

Cell Cycle Regulation Group, Institute of Cancer Research, University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.10678DOI Listing
November 2003

Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells.

Int J Cancer 2003 Sep;106(4):486-95

Cell Cycle Regulation Group, Institute of Cancer Research, University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.11290DOI Listing
September 2003

Non-apoptogenic killing of hela cervical carcinoma cells after short exposure to the alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).

J Cell Biochem 2003 Aug;89(6):1222-34

Cell Cycle Regulation Group, Institute of Cancer Research, Faculty of Medicine, University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.10586DOI Listing
August 2003

Phosphorylation regulates the interaction and complex formation between wt p53 protein and PARP-1.

J Cell Biochem 2003 Aug;89(6):1260-84

Cell Cycle Regulation Unit, Institute of Cancer Research, University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.10569DOI Listing
August 2003

Central and carboxy-terminal regions of human p53 protein are essential for interaction and complex formation with PARP-1.

J Cell Biochem 2003 May;89(2):220-32

Institute of Cancer Research, University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.10521DOI Listing
May 2003

Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy.

Int J Cancer 2002 Sep;101(2):128-36

Institute of Cancer Research, Faculty of Medicine, University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.10580DOI Listing
September 2002

Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1.

Cancer Res 2002 Aug;62(15):4206-11

Department of Clinical Pharmacology, Uppsala University Hospital, Uppsala, Sweden.

View Article

Download full-text PDF

Source
August 2002

Anti-SLA seropositive autoimmune hepatitis sera recognize distinct subunits of glutathione S-transferase: high prevalence of the Ya autoantigen.

Cell Mol Biol (Noisy-le-grand) 2002 May;48(3):301-7

Institute of Cancer Research, University of Vienna, Austria.

View Article

Download full-text PDF

Source
May 2002